Prestige Biopharma's Study Confirms HD204 as a Strong Biosimilar to Avastin for Lung Cancer Prestige Biopharma has unveiled significant topline findings from their SAMSON-II study, showcasing HD204 as a promising biosimilar to Avastin for lung cancer treatment.

Prestige Biopharma's Study Confirms HD204 as a Strong Biosimilar to Avastin for Lung Cancer #Singapore #Avastin #Prestige_Biopharma #HD204